You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Montanide

Showing 1 - 25 of 229
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumors, Esophageal Tumors, Esophagus Tumor Trial run by the National Cancer Institute (NCI) (Nivolumab, Entinostat, Montanide(R)

Not yet recruiting
  • Neoplasms
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 16, 2023

Cancer, Tumor Trial in Frankfurt (NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51)

Completed
Has Results
  • Cancer
  • Neoplasm
  • NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51
  • Frankfurt, Germany
    Krankenhaus Nordwest
Oct 3, 2022

Immune Response Trial in Oxford (Keyhole-Limpet Hemocyanin, Saline, Montanide ISA 51 VG)

Recruiting
  • Immune Response
  • Keyhole-Limpet Hemocyanin
  • +3 more
  • Oxford, United Kingdom
    NIHR Oxford Experimental Medicine Clinical Research Facility
May 16, 2023

Breast Cancer, Breast Tumors Trial in Fayetteville, Little Rock (Chemovax - P10s-PADRE/ MONTANIDE™ ISA 51 VG + Doxorubicin +

Completed
  • Breast Cancer
  • Breast Neoplasms
  • Chemovax - P10s-PADRE/ MONTANIDE™ ISA 51 VG + Doxorubicin + Cyclophosphamide + Docetaxel (or Paclitaxel)
  • Fayetteville, Arkansas
  • +1 more
Jan 26, 2023

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New York (NY-ESO-1 OLP4, NY-ESO-1 OLP4 +

Completed
Has Results
  • Epithelial Ovarian Cancer
  • +2 more
  • NY-ESO-1 OLP4
  • +2 more
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Melanoma (Skin) Trial in Tampa (MART-1, NY-ESO-1, gp100:209-217(210M))

Completed
  • Melanoma (Skin)
  • MART-1
  • +5 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 17, 2023

Melanoma Trial in New York (DC Vaccine, Montanide Vaccine, Poly-ICLC)

Completed
  • Melanoma
  • DC Vaccine
  • +2 more
  • New York, New York
  • +1 more
Sep 13, 2022

NSCLC, Non-Small Cell Lung Carcinoma, NSCLC Trial run by the National Cancer Institute (NCI) (biological, drug, device)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Montanide (Registered Trademark) ISA-51 VG Adjuvant
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Melanoma (Skin) Trial in Tampa (biological, drug, procedure)

Active, not recruiting
  • Melanoma (Skin)
  • NY-ESO-1 157-165 (165V)
  • +5 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 17, 2023

Triple Negative Breast Cancer, Breast Tumors Trial in Fayetteville, Little Rock (P10s-PADRE with MONTANIDE™ ISA 51 VG +

Active, not recruiting
  • Triple Negative Breast Cancer
  • Breast Neoplasms
  • P10s-PADRE with MONTANIDE™ ISA 51 VG + Doxorubicin + Cyclophosphamide + Paclitaxel
  • Doxorubicin + Cyclophosphamide + Paclitaxel
  • Fayetteville, Arkansas
  • +1 more
Aug 18, 2022

Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma Trial in Buffalo, Rochester (biological,

Active, not recruiting
  • Partial Response of Multiple Myeloma or Plasma Cell Leukemia
  • Plasma Cell Myeloma
  • Incomplete Freund's Adjuvant
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 12, 2022

Colo-rectal Cancer Trial (biological, drug, procedure)

Not yet recruiting
  • Colo-rectal Cancer
  • Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
  • +8 more
  • (no location specified)
Aug 28, 2023

Non Small Cell Lung Cancer Trial in Leiden, Rotterdam (TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51))

Recruiting
  • Non Small Cell Lung Cancer
  • TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)
  • Leiden, Zuid-Holland, Netherlands
  • +1 more
Jun 1, 2023

Tumors Trial in New York (NY-ESO-1 Protein Vaccine)

Completed
Has Results
  • Tumors
  • NY-ESO-1 Protein Vaccine
  • New York, New York
  • +1 more
Nov 29, 2021

COPD, Lung Non-Small Cell Carcinoma, Pneumonia Trial in Buffalo (Quality-of-Life Assessment, Questionnaire Administration,

Recruiting
  • Chronic Obstructive Pulmonary Disease
  • +7 more
  • Quality-of-Life Assessment
  • +2 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 20, 2022

Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer Trial in New York (NY-ESO-1 peptide vaccine)

Completed
Has Results
  • Fallopian Tube Cancer
  • +2 more
  • NY-ESO-1 peptide vaccine
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma Trial in

Recruiting
  • Advanced Head and Neck Squamous Cell Carcinoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Indianapolis, Indiana
  • +4 more
Aug 19, 2022

Chronic Lymphocytic Leukemia Trial in Herlev (PD-L1, PD-L2 peptides with Montanide ISA51)

Completed
  • Chronic Lymphocytic Leukemia
  • PD-L1, PD-L2 peptides with Montanide ISA51
  • Herlev, Denmark
    Herlev Hospital
Feb 4, 2022

Tumors by Site, Metastatic Cancer Trial (P10s-PADRE)

Withdrawn
  • Neoplasms by Site
  • Metastatic Cancer
  • (no location specified)
Mar 15, 2021

Yellow Fever, Yellow Fever Immunisation Trial in Iowa City, Saint Louis (drug, biological, other)

Completed
  • Yellow Fever
  • Yellow Fever Immunisation
  • Iowa City, Iowa
  • +1 more
Jun 24, 2021

Unresectable or Metastatic Melanoma Trial in Australia, United States (Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4

Terminated
Has Results
  • Unresectable or Metastatic Melanoma
  • Ipilimumab
  • +3 more
  • New York, New York
  • +4 more
Oct 3, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Philadelphia (OC-L/Montanide ISA 51 VG, Ampligen,

Terminated
Has Results
  • Ovarian Cancer
  • +2 more
  • OC-L/Montanide ISA 51 VG
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Oct 18, 2021

Basal Cell Carcinoma Trial in Hellerup (PD-L1)

Completed
  • Basal Cell Carcinoma
  • PD-L1
  • Hellerup, Hovedstaden, Denmark
    Herlev and Gentofte Hospital
Oct 2, 2020

Melanoma Trial in Lausanne (2 vaccine injections in 1 limb, 2 vaccine injections in distinct limbs, 2 "vaccine injections" in

Terminated
Has Results
  • Melanoma
  • 2 vaccine injections in 1 limb
  • +2 more
  • Lausanne, Vaud, Switzerland
    Oncology Department, CHUV
May 26, 2020

Melanoma Trial in Lausanne, Geneva (Melan-A ELA + Montanide, Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide, Melan-A -ELA +

Completed
Has Results
  • Melanoma
  • Melan-A ELA + Montanide
  • +4 more
  • Lausanne, Vaud, Switzerland
  • +1 more
Jun 2, 2020